Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

The poly(ADP‐ribose) polymerase‐1/2 inhibitor veliparib is active against tumors deficient in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended‐release (ER) were evaluated in patients with advanced solid tumors. This phase I study assessed veliparib‐ER up to 800 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010916/
https://www.ncbi.nlm.nih.gov/pubmed/29733524
http://dx.doi.org/10.1002/cam4.1488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010916/
https://www.ncbi.nlm.nih.gov/pubmed/29733524
http://dx.doi.org/10.1002/cam4.1488

Ejemplares similares